Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Company profile
Ticker
FATE
Exchange
Website
CEO
John Wolchko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Fate Therapeutics (UK) Ltd. • Tfinity Therapeutics, Inc. • Fate Therapeutics B.V. • Senescea Therapeutics, Inc. ...
FATE stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
28 Feb 23
8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
28 Feb 23
8-K
Termination of a Material Definitive Agreement
5 Jan 23
8-K
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
7 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
3 Aug 22
8-K
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
30 Jun 22
8-K
Departure of Directors or Certain Officers
13 Jun 22
Transcripts
FATE
Earnings call transcript
2022 Q4
28 Feb 23
FATE
Earnings call transcript
2022 Q3
4 Nov 22
FATE
Earnings call transcript
2022 Q2
4 Aug 22
FATE
Earnings call transcript
2022 Q1
5 May 22
FATE
Earnings call transcript
2021 Q4
1 Mar 22
FATE
Earnings call transcript
2021 Q3
5 Nov 21
FATE
Earnings call transcript
2021 Q2
5 Aug 21
FATE
Earnings call transcript
2021 Q1
6 May 21
FATE
Earnings call transcript
2020 Q4
25 Feb 21
FATE
Earnings call transcript
2020 Q3
6 Nov 20
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
10 Mar 23
SC 13G
Capital World Investors
13 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4
J Scott Wolchko
7 Feb 23
4
Bahram Valamehr
7 Feb 23
4
CINDY TAHL
7 Feb 23
4
Brian T. Powl
7 Feb 23
4
Edward J Dulac III
7 Feb 23
4
Yu-Waye Chu
7 Feb 23
SC 13G
STATE STREET CORP
3 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm |
| Cash burn (monthly) | 6.92 mm | 6.02 mm | 21.47 mm | 25.70 mm | 25.13 mm | 20.68 mm |
| Cash used (since last report) | 18.63 mm | 16.21 mm | 57.80 mm | 69.17 mm | 67.64 mm | 55.67 mm |
| Cash remaining | 57.93 mm | 60.35 mm | 18.76 mm | 7.39 mm | 8.92 mm | 20.89 mm |
| Runway (months of cash) | 8.4 | 10.0 | 0.9 | 0.3 | 0.4 | 1.0 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 221 |
| Opened positions | 34 |
| Closed positions | 47 |
| Increased positions | 94 |
| Reduced positions | 58 |
| 13F shares | Current |
|---|---|
| Total value | 1.06 tn |
| Total shares | 105.60 mm |
| Total puts | 83.80 k |
| Total calls | 86.30 k |
| Total put/call ratio | 1.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Redmile | 12.96 mm | $130.74 bn |
| BLK Blackrock | 9.73 mm | $98.14 bn |
| Vanguard | 7.97 mm | $80.44 bn |
| STT State Street | 5.94 mm | $59.89 bn |
| Capital World Investors | 5.59 mm | $56.42 bn |
| BLVGF Bellevue | 4.86 mm | $49.05 bn |
| ARK Investment Management | 4.21 mm | $42.53 bn |
| JNJ Johnson & Johnson | 3.38 mm | $34.09 bn |
| Millennium Management | 2.86 mm | $28.90 bn |
| T. Rowe Price | 2.66 mm | $26.83 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Feb 23 | Yu-Waye Chu | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Edward J Dulac III | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Brian T. Powl | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Cindy Tahl | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 425,000 | 2.88 mm | 425,000 |
| 6 Feb 23 | Bahram Valamehr | Stock Option Common Stock | Grant | Acquire A | No | No | 6.77 | 450,000 | 3.05 mm | 450,000 |
News
Citigroup Maintains Buy on Fate Therapeutics, Raises Price Target to $10
2 Mar 23
Expert Ratings for Fate Therapeutics
1 Mar 23
EF Hutton Reiterates Buy on Fate Therapeutics, Maintains $10 Price Target
1 Mar 23
Fate Therapeutics Q4 EPS $(0.58) Beats $(0.86) Estimate, Sales $44.36M Beat $16.72M Estimate
28 Feb 23
Earnings Scheduled For February 28, 2023
28 Feb 23
Press releases
FATE FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm's Attorneys, Mar. 22nd Deadline Pending in Securities Class Action
21 Mar 23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
21 Mar 23
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
21 Mar 23
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
21 Mar 23
FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders
21 Mar 23